Pubblicazioni

Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease

2017 - GASTROENTEROLOGY

Hyams, Jeffrey S.; Dubinsky, Marla C.; Baldassano, Robert N.; Colletti, Richard B.; Cucchiara, Salvatore; Escher, Johanna; Faubion, William; Fell, John; Gold, Benjamin D.; Griffiths, Anne; Koletzko, Sibylle; Kugathasan, Subra; Markowitz, James; Ruemmele, Frank M.; Veereman, Gigi; Winter, Harland; Masel, Nicholas; Shin, Chu Ri; Tang, Kezhen L.; Thayu, Meena

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4). A double-blind, multicentre, phase 3, randomised, placebo-controlled trial

2015 - THE LANCET ONCOLOGY

Saad, Fred; Fizazi, Karim; Jinga, Viorel; Efstathiou, Eleni; Fong, Peter C; Hart, Lowell L; Jones, Robert; Mcdermott, Raymond; Wirth, Manfred; Suzuki, Kazuhiro; Maclean, David B; Wang, Ling; Akaza, Hideyuki; Nelson, Joel; Scher, Howard I; Dreicer, Robert; Webb, Iain J; de Wit, Ronald; Collaborators, ; Tubaro, Andrea